Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock - Altimmune (NASDAQ:ALT)

Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock - Altimmune (NASDAQ:ALT)

GAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17,045,454 shares of its common stock (or pre-funded warrants in…

Biotech Altimmune raises $75M for Phase 3 MASH liver drug trial

17M new shares and pre-funded warrants bring Altimmune about $75M in gross proceeds to back its planned Phase 3 MASH trial and other needs.